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Fibulin 1 is downregulated through promoter hypermethylation in
gastric cancer
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Tumour suppressor genes (TSGs) were frequently inactivated through promoter hypermethylation in gastric carcinoma as well as
pre-malignant gastric lesions, suggesting that promoter hypermethylation can be used as a marker to define novel TSGs and also
biomarkers for early detection of gastric cancer. In an effort to search for such genes aberrantly methylated in gastric cancer
development, fibulin 1 (FBLN1) was found as a candidate TSG epigenetically downregulated in gastric cancer. FBLN1 expression was
downregulated in all of gastric cancer cell lines used (100%, 7 out of 7) and the primary gastric carcinoma tissues (84%, 86 out of 102)
and significantly restored after pharmacological demethylation. Hypermethylation of the FBLN1 promoter was frequently (71%, 5 out
of 7) detected in gastric cancer cell lines and primary gastric carcinoma tissues. Ectopic expression of FBLN1 led to the growth
inhibition of gastric cancer cells through the induction of apoptosis. In summary, FBLN1 was identified as a novel candidate TSG
epigenetically downregulated in gastric cancer.
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Gastric cancer is the second most important cause of cancer death
worldwide. Pathogenesis of gastric adenocarcinoma is believed to
be a stepwise process resulting from aberrant oncogene activation
and tumour suppressor gene (TSG) inactivations (Hanahan and
Weinberg, 2000; Ponder, 2001; Ushijima and Sasako, 2004).
Oncogenes, once activated, can promote carcinogenesis by
conferring growth advantages. In contrast, TSGs have tumour-
inhibitory functions and need to be inactivated during carcino-
genesis. Oncogenes are activated mainly through genetic alterations,
whereas aberrant TSG inactivation can result from both genetic
and epigenetic alterations. Epigenetic alterations such as promoter
hypermethylation can lead to the transcriptional silencing of TSGs,
which is important for preventing cancer development. Given that
most, if not all, TSGs can be inactivated through promoter
hypermethylation in human cancers, promoter hypermethylation
has been recognised as one of the most important markers for
identifying novel TSGs (Jones and Baylin, 2002; Esteller, 2008).
Moreover, promoter hypermethylation of tumour-related genes
has also been proposed as a novel biomarker for detecting cancer
and predicting prognosis (Jones and Baylin, 2007). We and others
have shown earlier that many tumour-related genes were
frequently silenced through promoter hypermethylation in gastric
carcinoma as well as pre-malignant gastric lesions (Leung et al,
2001; Lee et al, 2002; To et al, 2002; Chan et al, 2004; Choi and Wu,
2005; Chan and Rashid, 2006; Sato and Meltzer, 2006; Cheng et al,
2007; Ushijima, 2007; Vogiatzi et al, 2007), suggesting that
promoter hypermethylation can be utilised as biomarkers for
early detection of gastric cancer.
In an attempt to identify novel TSGs silenced through promoter
hypermethylation in gastric carcinogenesis and novel epigenetic
biomarkers for the detection of gastric cancer, we have profiled
genes epigenetically silenced in a panel of gastric cancer cell lines.
We indeed found that many TSGs well known to be epigenetically
silenced in gastric cancer, such as SFRP2 (secreted frizzled-related
protein 2), PCDH10 (protocadherin 10), DKK3 (dickkopf homo-
logue 3) and UCHL1 (ubiquitin carboxyl-terminal esterase L1),
were markedly upregulated after pharmacological demethylation
in many gastric cancer cell lines. In this study, we focused on
fibulin 1 (FBLN1), which was significantly upregulated after
pharmacological demethylation in all (5 out of 5) gastric cancer
cell lines used.
Fibulin 1 belongs to a growing family of extracellular
glycoproteins with distinctive features of a fibulin-type C-terminal
domain preceded by tandem epidermal growth factor-like modules
(Kobayashi et al, 2007). Fibulins have been shown to modulate cell
morphology, growth, adhesion and motility. Dysregulation of
certain FBLNs occurs in a range of human cancers, such as
prostate cancer (Gallagher et al, 2005). Among them, FBLN1 and
FBLN2 (fibulin 2) were found to be downregulated and acted as
tumour suppressive genes in certain cancers such as prostate
cancer and breast cancer (Wlazlinski et al, 2007; Yi et al, 2007).
However, whether FBLN1 functions as a TSG in gastric cancer
remains unknown.
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MATERIALS AND METHODS
Cell lines, primary tissues and RNA/DNA extraction
Seven gastric cancer cell lines (AGS, Kato III, MKN28, MKN45,
SNU1, SNU16 and NCI-N87) were obtained from Riken Gene Bank
(Tsukuba, Ibaraki, Japan) and American Type Culture Collection
(ATCC, Manassas, VA, USA). Unless specifically indicated, cells
were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% foetal bovine serum at 5% CO2, 371C
and 95% humidity. For pharmacological demethylation, cells were
treated with 5 mM 5-aza-20-deoxycytidine (Aza) (Sigma, St Louis,
MO, USA) for 3 consecutive days. 5-Aza-20-deoxycytidine was
replenished every 24 h. An equivalent concentration of the vehicle
(DMSO) was used as the control. All primary tissues, including 102
gastric adenocarcinomas and 10 normal gastric specimens, were
obtained from the Endoscopy Centre of the Prince of Wales
Hospital, The Chinese University of Hong Kong. All specimens
were immediately snap-frozen in liquid nitrogen and stored at
801C until further processing. All subjects gave informed consent
for obtaining the study materials. The study protocol was
approved by the Clinical Research Ethics Committee of the
Chinese University of Hong Kong.
Total RNA and genomic DNA were extracted using Trizol
reagent (Invitrogen) according to the manufacturer’s instructions.
RT–PCR and quantitative real-time RT–PCR
Reverse transcription reaction was performed using 1 mg of total
RNA with Reverse Transcription System (Promega, Madison, WI,
USA). The mRNA expression levels of the FBLN1 were determined
by conventional RT–PCR with GoTaq polymerase (Promega) and
quantitative real-time PCR using the SYBR Green Master Mix Kit
and the ABI 7500 Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). Glyceraldehyde-3-phosphate dehydrogenase
was used as an internal control of RNA integrity. Primers used for
FBLN1 RT–PCR were FBLN1-F: 50-TGCGAATGCAAGACGG and
FBLN1-R: 50-CGTAGACGTTGGCACA.
Bisulphite treatment of DNA, methylation-specific PCR
Methylation status of FBLN1 was determined by methylation-
specific PCR (MSP) using bisulphate-modified genomic DNA as
the template. Genomic DNA was bisulphite-treated with the Zymo
DNA Modification Kit (Zymo Research, Orange, CA, USA)
according to the protocol provided. Methylation-specific PCR
was carried out for 40 cycles with annealing temperature at 621C,
as described earlier (Cheng et al, 2007). Methylation-specific
primers were FBLN1M-F: 50-attaggagattcgcggtttc and FBLN1M-R:
50-gctccataaacgacgaacg, and the unmethylation-specific primers
were FBLN1U-F: 50-gattaggagatttgtggttttg and FBLN1U-R:
50-cacactccataaacaacaaaca. All primers were confirmed earlier for
not amplifying any non-bisulphite treated DNA.
Construction of FBLN1 expression plasmids
The FBLN1 expression plasmid was constructed by cloning of the
full-length FBLN1 open reading frame into mammalian expression
vector pcDNA3.1. The full-length FBLN1 open reading frame was
amplified from normal stomach cDNA using high-fidelity PFU
DNA polymerase (Invitrogen). The sequence and orientation of the
insert were confirmed by DNA sequencing.
Western blot analysis
A total of 20 mg of protein of each sample was resolved in 10%
sodium dodecyl sulphate/polyacrylamide gel electrophoresis. The
proteins on the polyacrylamide gel were transferred onto a
nitrocellulose membrane (Amersham, Piscataway, NJ, USA).
Polyclonal FBLN1 antibody (1 : 1000, 41C, overnight; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and the horseradish
peroxidase-conjugated goat anti-rabbit secondary antibody
(1 : 2000, room temperature, 1 h; Santa Cruz Biotechnology) were
applied for the detection of FBLN1 proteins. The blot was
visualised by using the enhanced chemiluminescence detection
system (Amersham) according to the manufacturer’s protocol.
Human b-actin was used as the control of protein integrity.
Cell growth assay
Transiently transfected MKN45 cells with empty pcDNA3.1 or
pcDNA3.1-FBLN1 vector were used for the monolayer colony-
formation assay. Cells were cultured overnight in a 12-well plate
(1.0 105 per well) and transfected with pcDNA3.1 or the FBLN1-
expressing vector using FuGENE 6 (Roche, Mannheim, Germany).
Forty-eight hours later, the transfectants were re-plated in triplicate
and cultured for 10–15 days in complete RPMI-1640 medium
containing G418 (400mg ml1). Surviving colonies were stained with
Gentian Violet after methanol fixation and visible colonies (X50
cells) were counted. The experiments were repeated three times.
Flow cytometric analysis
Cell apoptosis was determined by the detection of sub-G1
distribution with flow cytometric analysis. Briefly, cells transfected
with pcDNA3.1 or pcDNA3.1-FBLN1 vector were harvested and
washed twice with PBS. The cells were then fixed in ice-cold
ethanol for at least 1 h. After washing out ethanol, the fixed cells
were treated with 0.01% RNase (10 mg ml1; Sigma) for 10 min at
371C and then stained with 0.05% propidium iodide for 20 min at
41C in the dark. The cell cycle distribution was determined using a
FACScan flow cytometer (Becton Dickinson, Mountain View, CA,
USA) and 10 000 cells were analysed with the MultiCycle software
package (Phoenix, San Diego, CA, USA).
RESULTS
Upregulation of FBLN1 expression in gastric cancer cell
lines after Aza treatment
The expression of FBLN1 in gastric cancer cell lines, before and after
Aza treatment, was determined by quantitative real-time RT–PCR.
Fibulin 1 expression was significantly upregulated in all five gastric
cancer cell lines (AGS, Kato III, MKN28, MKN45 and NCI-N87) after
Aza treatment (Figure 1A and B). In addition, the expression of
FBLN1 was downregulated in all five gastric cancer cell lines and two
extra gastric cancer cell lines (SNU1 and SNU16) (Figure 1C),
indicating that FBLN1 is most likely one novel TSG that is silenced
through promoter hypermethylation in gastric cancer.
Promoter hypermethylation of FBLN1 in gastric cancer cell
lines
A typical CpG island (CGI) was found around FBLN1 exon 1 using
the following criteria: GC content 455%, ObsCpG/ExpCpG 40.65
and length 4500 bp (Figure 2A). The methylation status of this
CGI in gastric cancer cells was determined by MSP. As shown in
Figure 2B, full methylation was detected in five gastric cancer cell
lines, whereas the other two cell lines showed partial or no
methylation of FBLN1 CGI.
Downregulation and promoter hypermethylation of FBLN1
in primary tumours
To further confirm the promoter CGI hypermethylation-mediated
FBLN1 silencing in primary gastric carcinomas, FBLN1 expression
and FBLN1 promoter methylation in primary gastric carcinoma
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tissues, adjacent non-tumour gastric tissues and normal gastric
tissues were analysed by quantitative real-time RT–PCR and MSP,
respectively. Fibulin 1 expression was significantly downregulated
in most of the tumour tissues compared with adjacent non-tumour
tissues (Figure 3A). In addition, promoter methylation was
frequently detected in tumour samples but not in adjacent non-
tumour and normal gastric tissue samples (Figure 3B), high-
lighting a tumour-specific hypermethylation of the FBLN1
promoter. There was no significant association between FBLN1
methylation and clinical characteristics such as age, gender,
Helicobacter pylori infection, tumour grade, Lauren classification
and differentiation (Table 1).
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Figure 2 FBLN1 promoter is hypermethylated in gastric cancer cell lines. (A) Fibulin 1 has a typical CpG island around exon 1. CpG island was plotted by
the GeneTool program. The position of MSP primers is indicated by arrows. (B) The methylation status of the FBLN1 promoter was determined by MSP. M:
methylation; U: unmethylation.
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Figure 1 Pharmacological demethylation reactivates FBLN1 expression in gastric cancer cell lines. Relative FBLN1 expressions before and after Aza
treatment were determined by quantitative real-time RT–PCR (A) and conventional RT–PCR (B). GAPDH was used to normalise the template amount.
Representative results are shown. (C) Expression of FBLN1 in a panel of gastric cancer cell lines was determined by RT–PCR as in (B).
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Figure 3 Fibulin 1 is downregulated and hypermethylated in primary gastric carcinoma tissues. (A) The expression of FBLN1 in gastric carcinoma and
adjacent non-tumour tissues was determined by quantitative real-time RT–PCR as in Figure 1A. (B) The methylation status of the FBLN1 promoter in
primary gastric carcinoma and adjacent non-tumour tissues was determined by MSP as in Figure 2B. Representative results are shown.
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Growth-inhibitory function of FBLN1
Current data indicate that FBLN1 might have a tumour suppressive
function. We investigated its tumour suppressive function by a
gain-of-function strategy with the monolayer colony-formation
assay. After re-expression of FBLN1 in MKN45 cells, the number
of colonies formed on the plate was significantly reduced (Po0.01)
(Figure 4A and B). The growth inhibition was caused by an increase
in cell apoptosis, as the numbers of cells with sub-G1 distribution
increased significantly after FBLN1 re-expression (Figure 4C).
DISCUSSION
Over the past several years, many TSGs have been found to be
epigenetically inactivated in gastric cancer, indicating that
epigenetic silencing of TSGs is one of the major molecular
alterations in the process of gastric carcinogenesis (Lee et al, 2002;
To et al, 2002; Choi and Wu, 2005; Chan and Rashid, 2006; Sato
and Meltzer, 2006; Cheng et al, 2007). In this study, FBLN1 was
identified as another candidate TSG whose inactivation may
contribute to gastric carcinogenesis. It was frequently down-
regulated through promoter hypermethylation in gastric cancer
cell lines and primary gastric carcinoma tissues. The ectopic
expression of FBLN1 led to the growth inhibition of gastric cancer
cells, indicating that FBLN1 functions as a novel TSG epigenetically
silenced in gastric cancer.
There is growing evidence that hypermethylation of the TSG
promoter represents one of the major molecular alterations in
cancer development. Promoter hypermethylation can be used as a
sensitive marker not only for TSG identification but also for cancer
diagnosis and prognosis prediction (Jones and Baylin, 2002, 2007;
Esteller, 2008). Fibulin 1 was identified in this study as a novel
candidate TSG epigenetically inactivated in gastric cancer. How-
ever, we could not find any significant association of FBLN1
promoter methylation with clinical characteristics, including age,
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Figure 4 Fibulin 1 functions as a tumour suppressor gene in gastric cancer cell line MKN45. The effect of ectopic FBLN1 expression on tumour cell
growth was investigated by the monolayer colony-formation assay (A). Quantitative analyses of colony numbers are shown in the right panel as values of
mean±standard deviation. P-values were calculated using Student’s t-test. The asterisk indicates statistically significant difference (Po0.01). The expression
of FBLN1 after transfection was confirmed by western blotting analysis (B). (C) The rate of apoptosis before and after FBLN1 expression was determined
by flow cytometry. Values are shown as mean±s.d. from triplicate experiments. P-values were calculated using Student’s t-test. The asterisk indicates
statistically significant difference (Po0.01).
Table 1 Clinicopathological features of FBLN1 methylation in gastric
cancer
Characteristics Methylated (n) Unmethylated (n) P-value
Age (years)
Mean±s.d. 65.4±13.4 67.5±10.5 0.486
Gender
M 50 6 0.128
F 36 10
Helicobacter pylori infection
Positive 30 2 0.346
Negative 26 4
Lauren
Diffuse 25 6 0.058
Intestinal 38 2
Differentiation
Poor (or no) 33 8 0.114
Moderate 24 1
Well 6 0
TNM stage
I 14 1 0.246
II 16 1
III 24 6
IV 21 7
FBLN1¼ fibulin 1.
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gender, H. pylori infection, tumour grade, Lauren classification
and differentiation. This could be due to the limited resolution of
methylation analysis used in this study. Other methylation
analyses with higher resolution, such as quantitative methyla-
tion-specific analysis using sequenom or Taqman real-time PCR,
are warranted to assess whether FBLN1 promoter methylation is
useful for detecting early gastric cancer and predicting prognosis.
Although promoter methylation frequently inactivates FBLN1 in
gastric cancer cell lines, we cannot exclude the presence of other
mechanisms for the loss of function of FBLN1, such as defects in
histone remodelling. For instance, the FBLN1 promoter was not
significantly methylated in MKN45, which did not express FBLN1
(Figures 1C and 2B). In addition, we did not find any gastric cancer cell
line with high level of FBLN1 expression, indicating that FBLN1 is
inactivated mainly at the transcriptional level in gastric cancer.
However, defects in FNLB1 maturation and mislocalisation have been
found in other types of cancer, such as breast cancer (Pupa et al, 2004).
Interestingly, FBLN1 has four different variants that share a
common promoter and a transcriptional start site (Pan et al, 1999).
In this study, the longest isoform, which is the major isoform
constitutively expressed in multiple tissues, was used for
functional assays (Figure 4). The primers used in this study for
RT–PCR analysis could reveal the expression status of all four
isoforms, and no significant expression of FBLN1 was found in all
gastric cancer cell lines (Figure 1C), indicating that the imbalanced
expression of different isoforms is unlikely to be a relevant
mechanism for FBLN1 inactivation in gastric cancer.
Current evidence suggests that FBLN1 plays a tumour suppres-
sive role not only in gastric cancer but also in other cancers such as
breast cancer and prostate cancer (Pupa et al, 2004; Wlazlinski
et al, 2007). Fibulin 1 overexpression is correlated with better
prognosis in breast cancer, and FBLN1 is downregulated in
prostate cancer cells. The molecular mechanism of how FBLN1
suppresses tumorigenesis is not yet fully understood. Its expres-
sion can suppress cell motility and inhibit the phosphorylation of
extracellular signal-regulated kinase and myosin light chain (Twal
et al, 2001). Moreover, FBLN1 can reduce the intracellular calcium
level, which is important for the activation of multiple signal
cascades such as the Ras/MAPK pathway (Twal et al, 2001; Jin
et al, 2006, 2007). Interestingly, FBLN1 plays an important role in
human papillomavirus (HPV) E6-mediated oncogenesis (Du et al,
2002). Fibulin 1 can interact with HPV E6 including cancer-related
HPV E6s and the transforming bovine papillomavirus 1 (BPV1) E6.
Significantly, FBLN1 expression specifically inhibited both BPV1
and HPV16 E6-mediated cellular transformation. Although no
significant association between HPV infection and gastric cancer
has been found, it might be worthwhile to investigate whether
FBLN1 is involved in the interaction of H. pylori with gastric
epithelial cells.
In summary, we identified FBLN1 as a novel candidate TSG
epigenetically silenced in gastric cancer.
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